Election Impact, Moonshot, and Big Pharma
In this article Fierce Biotech reports the surprising impact that the election results had on biopharma stocks.
According to AJMC.com Vice President Joe Biden’s Cancer Moonshot initiative will be in limbo due to the results of this past week’s election.
In this piece from the Cancer Letter, there is speculation that Trump’s unanticipated victory upended what many in oncology expected to be a smooth transition for federal priorities in health care. Clinton had pledged to “take up the charge” on the moonshot, whereas the Trump campaign was mum on the subject (The Cancer Letter, Sept. 23).
Forbes Magazine reports that UnitedHealth Group, the nation’s largest health insurer, will launch a nationally branded accountable care organization, committing more resources to a value-based care push designed to attract self-funded employers.
In recent days, Novartis chief Joe Jimenez and Amgen CEO Robert Bradway, among others, have spoken out publicly about pegging drug costs to their results as reported in this article by FiercePharma.